|
CH627446A5
(fr)
|
1978-01-17 |
1982-01-15 |
Debiopharm Sa |
Nouveaux derives de la benzamide.
|
|
GB8302483D0
(en)
|
1983-01-29 |
1983-03-02 |
Beecham Group Plc |
Compounds
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
US4870074A
(en)
|
1986-04-30 |
1989-09-26 |
Dainippon Pharmaceutical Co., Ltd. |
Substituted benzamide derivatives, for enhancing gastrointestinal motility
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
DK0710719T3
(da)
|
1990-01-12 |
2007-07-09 |
Amgen Fremont Inc |
Frembringelse af xenogene antistoffer
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
DE69127627T2
(de)
|
1990-08-29 |
1998-02-19 |
Genpharm Int |
Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
JP2529912B2
(ja)
|
1990-10-16 |
1996-09-04 |
帝国化学産業株式会社 |
ベンズアミド誘導体
|
|
US5395832A
(en)
|
1991-02-15 |
1995-03-07 |
Hokuriku Seiyaku Co., Ltd. |
Benzamide derivatives
|
|
TW219935B
(enExample)
|
1991-12-25 |
1994-02-01 |
Mitsubishi Chemicals Co Ltd |
|
|
US5236931A
(en)
|
1992-03-26 |
1993-08-17 |
A. H. Robins Company, Incorporated |
2-substituted benzamide and benzoate derivatives of 3-aminoquinuclidine and 3-quinuclidinol
|
|
US5610052A
(en)
|
1992-08-26 |
1997-03-11 |
Ribozyme Pharmaceuticals Inc. |
Enzymatic RNA with activity to ras
|
|
US5686482A
(en)
|
1994-04-28 |
1997-11-11 |
Yamanouchi Pharmaceutical Co., Ltd. |
N-(3-pyrrolidinyl) benzamide derivative
|
|
US5783568A
(en)
|
1994-06-10 |
1998-07-21 |
Sugen, Inc. |
Methods for treating cancer and other cell proliferative diseases
|
|
JPH0823980A
(ja)
|
1994-07-15 |
1996-01-30 |
Terumo Corp |
脳神経細胞のアポトーシス時に発現する核レセプターおよびそれをコードする核レセプター遺伝子
|
|
EP1978033A3
(en)
|
1995-04-27 |
2008-12-24 |
Amgen Fremont Inc. |
Human antibodies derived from immunized xenomice
|
|
WO1996034096A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5958792A
(en)
|
1995-06-07 |
1999-09-28 |
Chiron Corporation |
Combinatorial libraries of substrate-bound cyclic organic compounds
|
|
GB9525620D0
(en)
|
1995-12-15 |
1996-02-14 |
Glaxo Group Ltd |
Chemical compounds
|
|
EP0827742A1
(en)
|
1996-09-04 |
1998-03-11 |
Vrije Universiteit Brussel |
Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
|
|
GB9821483D0
(en)
|
1998-10-03 |
1998-11-25 |
Glaxo Group Ltd |
Chemical compounds
|
|
JP3354090B2
(ja)
|
1996-09-30 |
2002-12-09 |
シエーリング アクチエンゲゼルシャフト |
分化誘導剤
|
|
US6174905B1
(en)
|
1996-09-30 |
2001-01-16 |
Mitsui Chemicals, Inc. |
Cell differentiation inducer
|
|
ATE549918T1
(de)
|
1996-12-03 |
2012-04-15 |
Amgen Fremont Inc |
Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
|
|
GB9625145D0
(en)
|
1996-12-03 |
1997-01-22 |
Smithkline Beecham Plc |
Novel compounds
|
|
JPH10330254A
(ja)
|
1997-04-01 |
1998-12-15 |
Kissei Pharmaceut Co Ltd |
翼状片の進行および術後の再発抑制剤
|
|
US6444849B1
(en)
|
1997-06-25 |
2002-09-03 |
Mitsubishi Chemical Corporation |
Amide derivatives
|
|
AU737018B2
(en)
|
1997-07-25 |
2001-08-09 |
Tsumura & Co. |
Pyridylacrylamide derivatives and nephritis remedies and TGF-beta inhibitors containing the same
|
|
BR9813365A
(pt)
|
1997-12-05 |
2004-06-15 |
Scripps Research Inst |
Método para produção e humanização de um anticorpo monoclonal de rato
|
|
US6140351A
(en)
|
1997-12-19 |
2000-10-31 |
Berlex Laboratories, Inc. |
Ortho-anthranilamide derivatives as anti-coagulants
|
|
US6673827B1
(en)
|
1999-06-29 |
2004-01-06 |
The Uab Research Foundation |
Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
|
|
JP4405602B2
(ja)
|
1998-04-16 |
2010-01-27 |
バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト |
ヒストン脱アセチル化酵素阻害剤
|
|
PL197181B1
(pl)
|
1998-05-15 |
2008-03-31 |
Astrazeneca Ab |
Pochodna benzamidowa, sposób jej wytwarzania, jej kompozycja farmaceutyczna i jej zastosowanie do wytwarzania leku
|
|
DE69919212T2
(de)
|
1998-12-23 |
2005-07-28 |
Eli Lilly And Co., Indianapolis |
Aromatische amiden
|
|
JP2000256194A
(ja)
|
1999-01-06 |
2000-09-19 |
Mitsui Chemicals Inc |
核内レセプタ作動薬およびその効果増強剤
|
|
AU4166400A
(en)
|
1999-02-11 |
2000-08-29 |
Cor Therapeutics, Inc. |
Alkenyl and alkynyl compounds as inhibitors of factor xa
|
|
WO2000055120A1
(en)
|
1999-03-17 |
2000-09-21 |
Astrazeneca Ab |
Amide derivatives
|
|
WO2000056153A1
(en)
|
1999-03-19 |
2000-09-28 |
Vertex Pharmaceuticals Incorporated |
Oral low dose butyrate compositions
|
|
JP2001081031A
(ja)
|
1999-08-30 |
2001-03-27 |
Schering Ag |
溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
|
|
IL148497A0
(en)
|
1999-09-08 |
2002-09-12 |
Sloan Kettering Inst Cancer |
Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
|
|
JP4360660B2
(ja)
|
1999-11-09 |
2009-11-11 |
三井化学株式会社 |
モノアシルフェニレンジアミン誘導体の精製法
|
|
AU784469B2
(en)
|
1999-12-08 |
2006-04-06 |
Serono Genetics Institute S.A. |
Full-length human cDNAs encoding potentially secreted proteins
|
|
TWI284639B
(en)
|
2000-01-24 |
2007-08-01 |
Shionogi & Co |
A compound having thrombopoietin receptor agonistic effect
|
|
US7288567B2
(en)
|
2000-03-24 |
2007-10-30 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
|
US7005439B2
(en)
|
2000-06-20 |
2006-02-28 |
Astrazeneca Ab |
Compounds
|
|
EP1170008A1
(en)
|
2000-07-07 |
2002-01-09 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Valproic acid and derivatives thereof as histone deacetylase inhibitors
|
|
US7569724B2
(en)
|
2000-09-29 |
2009-08-04 |
Topotarget Uk Limited |
Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
|
|
US20020103192A1
(en)
|
2000-10-26 |
2002-08-01 |
Curtin Michael L. |
Inhibitors of histone deacetylase
|
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
|
US6897220B2
(en)
|
2001-09-14 |
2005-05-24 |
Methylgene, Inc. |
Inhibitors of histone deacetylase
|
|
US6706686B2
(en)
|
2001-09-27 |
2004-03-16 |
The Regents Of The University Of Colorado |
Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
|
|
AR037460A1
(es)
|
2001-11-30 |
2004-11-10 |
Smithkline Beecham Plc |
Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion
|
|
US7993626B2
(en)
|
2007-01-11 |
2011-08-09 |
Immunomedics, Inc. |
Methods and compositions for F-18 labeling of proteins, peptides and other molecules
|
|
JP2006502117A
(ja)
|
2002-07-17 |
2006-01-19 |
タイタン ファーマシューティカルズ インコーポレイテッド |
抗腫瘍活性を上昇させるための化学療法薬物の組み合わせ
|
|
US20050215601A1
(en)
|
2002-09-25 |
2005-09-29 |
Santen Pharmaceutical Co., Ltd. |
Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient
|
|
US8163896B1
(en)
|
2002-11-14 |
2012-04-24 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
US7790867B2
(en)
|
2002-12-05 |
2010-09-07 |
Rosetta Genomics Inc. |
Vaccinia virus-related nucleic acids and microRNA
|
|
US20050054647A1
(en)
*
|
2002-12-27 |
2005-03-10 |
Detlev Schuppan |
New pharmaceutical combination
|
|
US7244751B2
(en)
|
2003-02-14 |
2007-07-17 |
Shenzhen Chipscreen Biosciences Ltd. |
Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
|
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
|
PE20050206A1
(es)
|
2003-05-26 |
2005-03-26 |
Schering Ag |
Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
|
|
MY142655A
(en)
|
2003-06-12 |
2010-12-15 |
Euro Celtique Sa |
Therapeutic agents useful for treating pain
|
|
US9005613B2
(en)
|
2003-06-16 |
2015-04-14 |
Immunomedics, Inc. |
Anti-mucin antibodies for early detection and treatment of pancreatic cancer
|
|
CN1284772C
(zh)
|
2003-07-04 |
2006-11-15 |
深圳微芯生物科技有限责任公司 |
具有分化和抗增殖活性的苯甲酰胺类组蛋白去乙酰化酶抑制剂及其药用制剂
|
|
WO2005046516A2
(en)
|
2003-11-10 |
2005-05-26 |
Angiotech International Ag |
Medical implants and anti-scarring agents
|
|
US20130189364A1
(en)
|
2004-07-09 |
2013-07-25 |
Robert Sabin |
Compositions and methods of potentiating adjuvant pharmaceuticals targeting latent viral infections
|
|
EP2946810A1
(en)
|
2005-02-03 |
2015-11-25 |
TopoTarget UK Limited |
Combination therapy using an HDAC inhibitor and Vincristine for treating cancer
|
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
JP5265204B2
(ja)
|
2005-03-04 |
2013-08-14 |
ライフスキャン・インコーポレイテッド |
成人膵臓由来間質細胞
|
|
AU2006244885B2
(en)
*
|
2005-05-09 |
2011-03-31 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
WO2006121521A2
(en)
|
2005-05-10 |
2006-11-16 |
Angiotech International Ag |
Soft tissue implants, anti-scarring agents, and therapeutic compositions
|
|
WO2006135479A2
(en)
|
2005-05-10 |
2006-12-21 |
Angiotech International Ag |
Anti-scarring agents, therapeutic compositions, and use thereof
|
|
WO2006121518A2
(en)
|
2005-05-10 |
2006-11-16 |
Angiotech International Ag |
Electrical devices, anti-scarring agents, and therapeutic compositions
|
|
WO2006121522A2
(en)
|
2005-05-10 |
2006-11-16 |
Angiotech International Ag |
Implantable sensors and pumps, anti-scarring agents, and therapeutic compositions
|
|
WO2007057440A2
(en)
|
2005-11-17 |
2007-05-24 |
Innate Pharma |
Improved methods of using phosphoantigen for the treatment of cancer
|
|
US20090247734A1
(en)
|
2005-12-14 |
2009-10-01 |
Hendrickson Wayne A |
Chemically Derivatized CD4 and Uses Thereof
|
|
CA2639070A1
(en)
|
2006-04-13 |
2007-11-01 |
Oncomethylime Sciences S.A. |
Novel tumour suppressor
|
|
US20070292351A1
(en)
|
2006-05-26 |
2007-12-20 |
Methylgene, Inc. |
Assay for efficacy of histone deacetylase inhibitors
|
|
MX337906B
(es)
|
2006-10-19 |
2016-03-28 |
Signal Pharm Llc |
Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
|
|
US7838234B2
(en)
|
2007-01-30 |
2010-11-23 |
Pharmacyclics, Inc. |
Methods for determining cancer resistance to histone deacetylase inhibitors
|
|
WO2009029342A2
(en)
|
2007-07-13 |
2009-03-05 |
The Johns Hopkins University |
B7-dc variants
|
|
JP5670731B2
(ja)
|
2007-08-15 |
2015-02-18 |
サイトキネティクス・インコーポレーテッドＣｙｔｏｋｉｎｅｔｉｃｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
ある種の化学物質、組成物、および方法
|
|
TW200924777A
(en)
|
2007-09-14 |
2009-06-16 |
Methylgene Inc |
Combination therapy
|
|
GB0802009D0
(en)
|
2008-02-04 |
2008-03-12 |
Chroma Therapeutics Ltd |
Biomarkers of aminopeptidase inhibition
|
|
JP2009209090A
(ja)
|
2008-03-04 |
2009-09-17 |
Mitsui Chemicals Inc |
殺虫剤及び該殺虫剤に含まれる化合物、並びに該化合物の使用方法
|
|
WO2009147781A1
(ja)
|
2008-06-02 |
2009-12-10 |
国立大学法人東京大学 |
抗がん剤
|
|
MX2011002250A
(es)
|
2008-08-25 |
2011-08-17 |
Amplimmune Inc |
Antagonistas de muerte celular programada-1 y métodos de uso de los mismos.
|
|
TWI453207B
(zh)
|
2008-09-08 |
2014-09-21 |
Signal Pharm Llc |
胺基三唑并吡啶，其組合物及使用其之治療方法
|
|
US20160041153A1
(en)
|
2008-11-12 |
2016-02-11 |
Kirk Brown |
Biomarker compositions and markers
|
|
CN101757626B
(zh)
|
2008-12-26 |
2012-12-12 |
鼎泓国际投资（香港）有限公司 |
含有胰岛素样生长因子-i受体抑制剂和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
|
|
CN101756957B
(zh)
|
2008-12-26 |
2012-11-14 |
鼎泓国际投资（香港）有限公司 |
含有青蒿素及青蒿素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
|
|
CN101837129B
(zh)
|
2009-03-19 |
2012-12-12 |
鼎泓国际投资（香港）有限公司 |
含cMet抑制剂、HDAC抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用
|
|
CN101836989B
(zh)
|
2009-03-19 |
2013-02-13 |
鼎泓国际投资（香港）有限公司 |
含有粉防己碱及粉防己碱类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
|
|
CA2779223A1
(en)
|
2009-10-27 |
2011-05-12 |
Caris Mpi, Inc. |
Molecular profiling for personalized medicine
|
|
JP2013510180A
(ja)
|
2009-11-06 |
2013-03-21 |
インフィニティ ファーマスーティカルズ、インク． |
ヘッジホッグ経路阻害剤の経口製剤
|
|
WO2011060328A1
(en)
|
2009-11-13 |
2011-05-19 |
Infinity Pharmaceuticals, Inc. |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
|
|
JP2013511549A
(ja)
|
2009-11-20 |
2013-04-04 |
インフィニティー ファーマシューティカルズ， インコーポレイテッド |
ヘッジホッグ関連癌の治療のための方法及び組成物
|
|
ES2730763T3
(es)
|
2010-02-11 |
2019-11-12 |
Celgene Corp |
Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos
|
|
WO2011120013A2
(en)
|
2010-03-26 |
2011-09-29 |
Trustees Of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
|
CA2795776A1
(en)
|
2010-04-06 |
2011-10-13 |
Caris Life Sciences Luxembourg Holdings, S.A.R.L. |
Circulating biomarkers for disease
|
|
JO2998B1
(ar)
|
2010-06-04 |
2016-09-05 |
Amgen Inc |
مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
|
|
US8993622B2
(en)
|
2010-06-11 |
2015-03-31 |
Eirium Ab |
Antiviral compounds
|
|
WO2012006584A2
(en)
|
2010-07-08 |
2012-01-12 |
Infinity Pharmaceuticals, Inc. |
Therapeutic regimens for hedgehog-associated cancers
|
|
WO2012006589A2
(en)
|
2010-07-08 |
2012-01-12 |
Infinity Pharmaceuticals, Inc. |
Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
|
|
EP2606353A4
(en)
|
2010-08-18 |
2014-10-15 |
Caris Life Sciences Luxembourg Holdings |
CIRCULATING BIOMARKERS FOR DISEASES
|
|
CN102441167B
(zh)
|
2010-10-12 |
2014-05-07 |
鼎泓国际投资（香港）有限公司 |
含有芹菜素及芹菜素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
|
|
US9808434B2
(en)
|
2011-01-27 |
2017-11-07 |
City Of Hope |
Compound for treating cancer and diabetes
|
|
WO2012115885A1
(en)
|
2011-02-22 |
2012-08-30 |
Caris Life Sciences Luxembourg Holdings, S.A.R.L. |
Circulating biomarkers
|
|
WO2012167086A2
(en)
|
2011-06-03 |
2012-12-06 |
President And Fellows Of Harvard College |
Methods of diagnosing and treating amyotrophic lateral sclerosis
|
|
US20140228233A1
(en)
|
2011-06-07 |
2014-08-14 |
Traci Pawlowski |
Circulating biomarkers for cancer
|
|
KR20140072014A
(ko)
|
2011-06-16 |
2014-06-12 |
카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. |
생물지표 조성물 및 방법
|
|
AU2012298794A1
(en)
|
2011-08-23 |
2013-04-04 |
Infinity Pharmaceuticals, Inc. |
Biomarkers predictive of therapeutic responsiveness to HSP90 inhibitors and uses thereof
|
|
WO2013039956A2
(en)
|
2011-09-14 |
2013-03-21 |
The Trustees Of Columbia University In The City Of New York |
Compositions and methods for treating mood disorders
|
|
PH12014500635B1
(en)
|
2011-09-30 |
2018-10-31 |
Dana Farber Cancer Inst Inc |
Therapeutic peptides
|
|
EP2785683B1
(en)
|
2011-11-30 |
2020-02-05 |
Ludwig Institute for Cancer Research Ltd. |
Inkt cell modulators and methods of using the same
|
|
WO2013085902A1
(en)
|
2011-12-05 |
2013-06-13 |
The University Of Texas M.D. |
Combination therapy methods for treating an inflammatory breast cancer
|
|
SG2014008304A
(en)
|
2012-02-01 |
2014-06-27 |
Compugen Ltd |
C10rf32 antibodies, and uses thereof for treatment of cancer
|
|
WO2013124867A1
(en)
|
2012-02-21 |
2013-08-29 |
Amrita Vishwa Vidyapeetham University |
Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
|
|
EP2823306A4
(en)
|
2012-03-09 |
2015-11-11 |
Caris Life Sciences Switzerland Holdings Gmbh |
BIOMARKER COMPOSITIONS AND METHODS
|
|
BR112014030466A2
(pt)
|
2012-06-06 |
2017-09-12 |
Bionor Immuno As |
peptídeos derivados de proteínas virais para uso como imunógenos e reagentes de dosagem
|
|
EA201492260A1
(ru)
|
2012-06-06 |
2015-08-31 |
Бионор Иммуно Ас |
Вакцина
|
|
KR20150023811A
(ko)
|
2012-06-21 |
2015-03-05 |
컴퓨젠 엘티디. |
암의 치료를 위한 lsr 항체 및 그의 용도
|
|
US10258596B2
(en)
|
2012-07-13 |
2019-04-16 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
|
US10314807B2
(en)
|
2012-07-13 |
2019-06-11 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
|
ES2941477T3
(es)
|
2012-08-13 |
2023-05-23 |
Univ Rockefeller |
Agonista de LXRbeta para el tratamiento de cáncer
|
|
CN109513003A
(zh)
|
2012-08-14 |
2019-03-26 |
Ibc药品公司 |
用于治疗疾病的t-细胞重定向双特异性抗体
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
KR101839864B1
(ko)
|
2012-09-21 |
2018-03-20 |
인텐시티 쎄라퓨틱스, 인코포레이티드 |
암을 치료하는 방법
|
|
CN104903450A
(zh)
|
2012-11-05 |
2015-09-09 |
普隆奈治疗公司 |
寡核苷酸癌症疗法的给药和施用
|
|
CA2890288A1
(en)
|
2012-11-16 |
2014-05-22 |
Merck Patent Gmbh |
Novel heterocyclic derivatives as modulators of kinase activity
|
|
US20150301058A1
(en)
|
2012-11-26 |
2015-10-22 |
Caris Science, Inc. |
Biomarker compositions and methods
|
|
CN103833626B
(zh)
|
2012-11-27 |
2015-11-25 |
深圳微芯生物科技有限责任公司 |
西达本胺的晶型及其制备方法与应用
|
|
KR20150090044A
(ko)
|
2012-11-29 |
2015-08-05 |
메르크 파텐트 게엠베하 |
아자퀴나졸린 카복사미드 유도체
|
|
ES2819573T3
(es)
|
2012-12-13 |
2021-04-16 |
Immunomedics Inc |
Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
|
|
LT2900277T
(lt)
|
2012-12-13 |
2022-04-11 |
Immunomedics, Inc. |
Antikūnų ir sn-38 imunokonjugatų dozės, skirtos pagerintam veiksmingumui ir sumažintam toksiškumui
|
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
CN105209068A
(zh)
|
2013-02-07 |
2015-12-30 |
免疫医疗公司 |
用于靶向癌症治疗的缀合至抗体的高效2-吡咯啉多柔比星的前药形式(p2pdox)
|
|
WO2014122551A1
(en)
|
2013-02-07 |
2014-08-14 |
Koninklijke Philips N.V. |
A lighting system having a controller that contributes to a selected light scene, and a method for controlling such a system
|
|
CN104056270B
(zh)
|
2013-02-21 |
2018-11-09 |
中国人民解放军军事医学科学院野战输血研究所 |
用于制备多器官损伤救治药物的组蛋白去乙酰化酶抑制剂
|
|
EP2964649B1
(en)
|
2013-03-05 |
2017-05-10 |
Merck Patent GmbH |
Triazolo[4,5-d]pyrimidine derivatives for the treatment of diseases such as cancer
|
|
US9617266B2
(en)
|
2013-03-05 |
2017-04-11 |
Merck Patent Gmbh |
Imidazopyrimidine derivatives
|
|
EP3305812B1
(en)
|
2013-03-14 |
2020-06-17 |
Bristol-Myers Squibb Company |
Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
|
|
JP2016517420A
(ja)
|
2013-03-14 |
2016-06-16 |
セラゴン ファーマシューティカルズ， インク． |
多環式エストロゲン受容体モジュレーター及びその使用
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
US20150071910A1
(en)
|
2013-03-15 |
2015-03-12 |
Genentech, Inc. |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
|
WO2014144791A2
(en)
|
2013-03-15 |
2014-09-18 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
|
EP2970965A2
(en)
|
2013-03-15 |
2016-01-20 |
Pronai Therapeutics, Inc. |
Dnai for the modulation of genes
|
|
CN104069106A
(zh)
|
2013-03-27 |
2014-10-01 |
南通瑞思医药技术有限公司 |
苯甲酰胺类化合物在制备激活潜伏艾滋病病毒药物中的应用
|
|
WO2014172637A1
(en)
|
2013-04-18 |
2014-10-23 |
Immune Design Corp. |
Gla monotherapy for use in cancer treatment
|
|
EP3003355A1
(en)
|
2013-05-24 |
2016-04-13 |
Cooper Human Systems LLC |
Methods and compositions for treatment of hiv infection
|
|
WO2014193999A2
(en)
|
2013-05-28 |
2014-12-04 |
Caris Science, Inc. |
Biomarker methods and compositions
|
|
AU2014281511A1
(en)
|
2013-06-19 |
2015-12-03 |
Seragon Pharmaceuticals, Inc. |
Estrogen receptor modulator and uses thereof
|
|
RU2015152171A
(ru)
|
2013-06-19 |
2017-07-25 |
Серагон Фармасьютикалз, Инк. |
Азетидиновые модуляторы эстрогеновых рецепторов и их применения
|
|
CA2915622C
(en)
|
2013-06-21 |
2020-08-18 |
Zenith Epigenetics Corp. |
Novel substituted bicyclic compounds as bromodomain inhibitors
|
|
WO2015007337A1
(en)
|
2013-07-19 |
2015-01-22 |
Bionor Immuno As |
Method for the vaccination against hiv
|
|
EP3024456A4
(en)
|
2013-07-26 |
2017-04-12 |
Update Pharma Inc. |
Combinatorial methods to improve the therapeutic benefit of bisantrene
|
|
SG11201600726QA
(en)
|
2013-07-29 |
2016-03-30 |
Merck Patent Gmbh |
1,3-disubstituted cyclopentane derivatives
|
|
WO2015017546A1
(en)
|
2013-07-30 |
2015-02-05 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Selective histone deactylase 6 inhibitors
|
|
RS56211B1
(sr)
|
2013-07-31 |
2017-11-30 |
Merck Patent Gmbh |
Oksohinazolinil-butanamid derivati
|
|
EA201690087A1
(ru)
|
2013-07-31 |
2016-08-31 |
Зенит Эпидженетикс Корп. |
Новые квиназолиноны как ингибиторы бромодомена
|
|
EP3030322A2
(en)
|
2013-08-05 |
2016-06-15 |
Cambridge Enterprise Limited |
Inhibition of cxcr4 signaling in cancer immunotherapy
|
|
NZ717552A
(en)
|
2013-08-07 |
2021-07-30 |
Merck Patent Gmbh |
Piperidine urea derivatives
|
|
WO2015023938A1
(en)
|
2013-08-16 |
2015-02-19 |
Rana Therapeutics, Inc. |
Epigenetic regulators of frataxin
|
|
CN103432077A
(zh)
|
2013-08-21 |
2013-12-11 |
北京淦航医药科技有限公司 |
西达苯胺固体分散制剂
|
|
US10966998B2
(en)
|
2013-09-05 |
2021-04-06 |
The Johns Hopkins University |
Cancer therapy via a combination of epigenetic modulation and immune modulation
|
|
WO2015037000A1
(en)
|
2013-09-11 |
2015-03-19 |
Compugen Ltd |
Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
|
|
AU2014319921A1
(en)
|
2013-09-11 |
2016-03-17 |
Compugen Ltd. |
Anti-VSTM5 antibodies and the use thereof in therapy and diagnosis
|
|
US20150087673A1
(en)
|
2013-09-26 |
2015-03-26 |
Rigel Pharmaceuticals, Inc. |
Methods for using and biomarkers for ampk-activating compounds
|
|
US20150094518A1
(en)
|
2013-09-27 |
2015-04-02 |
The Regents Of The University Of California |
Modular polymer platform for the treatment of cancer
|
|
EP3060550B1
(en)
|
2013-10-21 |
2019-05-15 |
Merck Patent GmbH |
Heteroaryl compounds as btk inhibitors and uses thereof
|
|
US9617521B2
(en)
|
2013-10-21 |
2017-04-11 |
Hemoshear, Llc |
In vitro model for a tumor microenvironment
|
|
US20170080093A1
(en)
|
2013-10-22 |
2017-03-23 |
Tyme, Inc. |
Tyrosine Derivatives And Compositions Comprising Them
|
|
KR101862493B1
(ko)
|
2013-10-25 |
2018-05-29 |
노파르티스 아게 |
Fgfr4 억제제로서의 고리-융합된 비시클릭 피리딜 유도체
|
|
US9457019B2
(en)
|
2013-11-07 |
2016-10-04 |
Deciphera Pharmaceuticals, Llc |
Methods for inhibiting tie-2 kinase useful in the treatment of cancer
|
|
JP6568093B2
(ja)
|
2013-11-07 |
2019-08-28 |
デシフェラ ファーマシューティカルズ，エルエルシー |
ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
|
|
WO2015073575A2
(en)
|
2013-11-12 |
2015-05-21 |
Centre For Probe Development And Commercialization |
Residualizing linkers and uses thereof
|
|
JP2016537345A
(ja)
|
2013-11-13 |
2016-12-01 |
ノバルティス アーゲー |
免疫応答を増強するためのｍＴＯＲ阻害剤
|
|
CN106029076B
(zh)
|
2013-11-18 |
2019-06-07 |
福马疗法公司 |
作为bet溴域抑制剂的苯并哌嗪组合物
|
|
US9388161B2
(en)
|
2013-11-18 |
2016-07-12 |
Forma Therapeutics, Inc. |
Tetrahydroquinoline compositions as BET bromodomain inhibitors
|
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
|
WO2015085210A1
(en)
|
2013-12-06 |
2015-06-11 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
|
WO2015086738A2
(en)
|
2013-12-11 |
2015-06-18 |
Bionor Immuno As |
Hiv vaccine
|
|
WO2015089380A2
(en)
|
2013-12-12 |
2015-06-18 |
Celcuity Llc |
Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent
|
|
US20160263092A1
(en)
|
2013-12-19 |
2016-09-15 |
Twi Biotechnology, Inc. |
Therapeutic uses of berberine formulations
|
|
US9783538B2
(en)
|
2013-12-20 |
2017-10-10 |
Astex Therapeutics Limited |
Bicyclic heterocycle compounds and their uses in therapy
|
|
BR112016014410A2
(pt)
|
2013-12-20 |
2018-02-20 |
The Broad Institute Inc. |
terapia de combinação com vacina de neoantígeno
|
|
WO2015096884A1
(en)
|
2013-12-23 |
2015-07-02 |
Merck Patent Gmbh |
Imidazopyrazinone derivatives
|
|
PT3086814T
(pt)
|
2013-12-23 |
2020-09-04 |
Bayer Pharma AG |
Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp
|
|
CA2939120A1
(en)
|
2014-01-10 |
2015-07-16 |
Rgenix, Inc. |
Lxr agonists and uses thereof
|
|
CN104771363A
(zh)
|
2014-01-14 |
2015-07-15 |
深圳微芯生物科技有限责任公司 |
一种西达本胺固体分散体及其制备方法与应用
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
WO2015110659A1
(en)
|
2014-01-27 |
2015-07-30 |
Bionor Immuno As |
Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response
|
|
WO2015110666A1
(en)
|
2014-01-27 |
2015-07-30 |
Bionor Immuno As |
Method for the vaccination against hiv
|
|
AU2015208032B2
(en)
|
2014-01-27 |
2020-07-30 |
Bionor Immuno As |
Dosage regimen for HIV vaccine
|
|
US9631013B2
(en)
|
2014-01-28 |
2017-04-25 |
Fibrogen, Inc. |
Therapeutic method for pancreatic cancer
|
|
WO2015113927A1
(en)
|
2014-01-29 |
2015-08-06 |
Bayer Pharma Aktiengesellschaft |
Amino-substituted isothiazoles
|
|
CA2937989A1
(en)
|
2014-01-29 |
2015-08-06 |
Bayer Pharma Aktiengesellschaft |
Amino-substituted isothiazoles
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
WO2015120382A1
(en)
|
2014-02-07 |
2015-08-13 |
The Johns Hopkins University |
Predicting response to epigenetic drug therapy
|
|
CA2936886A1
(en)
|
2014-02-27 |
2015-08-03 |
Merck Patent Gmbh |
Heterocyclic compounds as nav channel inhibitors and uses thereof
|
|
US9828399B2
(en)
|
2014-02-28 |
2017-11-28 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
TC-PTP inhibitors as APC activators for immunotherapy
|
|
SG10201807838SA
(en)
|
2014-03-11 |
2018-10-30 |
Council Queensland Inst Medical Res |
Determining cancer aggressiveness, prognosis and responsiveness to treatment
|
|
US9855270B2
(en)
|
2014-03-13 |
2018-01-02 |
Genentech, Inc. |
Methods and compositions for modulating estrogen receptor mutants
|
|
MA39741A
(fr)
|
2014-03-13 |
2017-01-18 |
Hoffmann La Roche |
Combinaisons thérapeutiques avec des modulateurs du récepteur des œstrogènes
|
|
US20150259420A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
CN106456628A
(zh)
|
2014-03-19 |
2017-02-22 |
无限药品股份有限公司 |
用于治疗PI3K‑γ介导的障碍的杂环化合物
|
|
UY36060A
(es)
|
2014-04-02 |
2015-10-30 |
Bayer Pharma AG |
Compuestos de azol sustituidos con amida
|
|
CN104974079A
(zh)
|
2014-04-02 |
2015-10-14 |
C&C生物医药有限公司 |
苯胺相关化合物的酰胺衍生物及其组合物
|
|
EP3129472A4
(en)
|
2014-04-03 |
2017-11-01 |
University of Maryland, Baltimore |
Microtentacle imaging in patient tumor samples
|
|
CN103880736B
(zh)
|
2014-04-04 |
2017-05-17 |
深圳微芯生物科技有限责任公司 |
一种e构型苯甲酰胺类化合物及其药用制剂与应用
|
|
WO2015157162A1
(en)
*
|
2014-04-06 |
2015-10-15 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Histone deacetylase as a modulator of pdl1 expression and activity
|
|
WO2015157093A1
(en)
|
2014-04-08 |
2015-10-15 |
Rigel Pharmaceuticals, Inc. |
2,3-disubstituted pyridine compounds as tgf-beta inhibitors and methods of use
|
|
NO2776305T3
(enExample)
|
2014-04-23 |
2018-01-27 |
|
|
|
JP2015209376A
(ja)
|
2014-04-24 |
2015-11-24 |
国立大学法人北海道大学 |
腫瘍特異的免疫増強剤
|
|
WO2015168465A1
(en)
|
2014-04-30 |
2015-11-05 |
Rgenix, Inc. |
Inhibitors of creatine transport and uses thereof
|
|
WO2015168614A2
(en)
|
2014-05-01 |
2015-11-05 |
Board Of Regents Of The University Of Nebraska |
Polymer compositions of histone deacetylase inhibitors and methods of use thereof
|
|
WO2015172747A1
(en)
|
2014-05-16 |
2015-11-19 |
Zhaoyin Wang |
Spirocyclic molecules as mth1 inhibitors
|
|
GB201409471D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
|
EP4397374A3
(en)
|
2014-05-28 |
2024-10-16 |
Mederis Diabetes, LLC |
Improved peptide pharmaceuticals for insulin resistance
|
|
WO2015184405A1
(en)
|
2014-05-30 |
2015-12-03 |
Medivation Technologies, Inc. |
Aromatic compounds, compositions and uses thereof
|
|
US11034757B2
(en)
|
2014-06-09 |
2021-06-15 |
Biomed Valley Discoveries, Inc. |
Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
|
|
TWI729644B
(zh)
|
2014-06-12 |
2021-06-01 |
美商西爾拉癌症醫學公司 |
N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
|
|
NZ726360A
(en)
|
2014-06-13 |
2018-04-27 |
Gilead Sciences Inc |
Phosphatidylinositol 3-kinase inhibitors
|
|
KR20170012558A
(ko)
|
2014-06-13 |
2017-02-02 |
길리애드 사이언시즈, 인코포레이티드 |
포스파티딜이노시톨 3-키나제 억제제
|
|
CA2952025A1
(en)
|
2014-06-13 |
2015-12-17 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
|
EA201692266A1
(ru)
|
2014-06-13 |
2017-06-30 |
Джилид Сайэнс, Инк. |
Ингибиторы фосфатидилинозитол-3-киназы
|
|
NZ726608A
(en)
|
2014-06-13 |
2018-04-27 |
Gilead Sciences Inc |
Phosphatidylinositol 3-kinase inhibitors
|
|
CA2987978C
(en)
|
2014-06-16 |
2022-08-16 |
Fundacion Para La Investigacion Medica Aplicada |
Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases
|
|
WO2015193339A1
(en)
|
2014-06-17 |
2015-12-23 |
Bayer Pharma Aktiengesellschaft |
3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
|
|
NO2717902T3
(enExample)
|
2014-06-20 |
2018-06-23 |
|
|
|
TW201613936A
(en)
|
2014-06-20 |
2016-04-16 |
Gilead Sciences Inc |
Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
|
|
AR100975A1
(es)
|
2014-06-24 |
2016-11-16 |
Gilead Sciences Inc |
Inhibidores de fosfatidilinositol 3-quinasa
|
|
WO2015200790A2
(en)
|
2014-06-26 |
2015-12-30 |
Yale University |
Compositions and methods to regulate renalase in the treatment of diseases and disorders
|
|
JP2017523166A
(ja)
*
|
2014-07-11 |
2017-08-17 |
ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ |
ヒト免疫不全ウイルスｉ（ｈｉｖ）の病理学的影響を減少及び／若しくは遅延させるか又は後天性免疫不全症候群（ａｉｄｓ）を発症するリスクを低減させる方法
|
|
JP6522732B2
(ja)
|
2014-07-11 |
2019-05-29 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖを治療するためのトール様受容体の調節因子
|
|
CN107072984B
(zh)
|
2014-07-15 |
2021-10-01 |
约翰·霍普金斯大学 |
源自骨髓的抑制细胞的抑制和免疫检查点阻断
|
|
CN104083763A
(zh)
|
2014-07-16 |
2014-10-08 |
中国人民解放军军事医学科学院野战输血研究所 |
组蛋白去乙酰化酶抑制剂在制备潜伏病毒激活剂中的应用
|
|
US20160016951A1
(en)
|
2014-07-17 |
2016-01-21 |
Merck Patent Gmbh |
Novel naphthyridines and isoquinolines and their use as cdk8/19 inhibitors
|
|
WO2016014890A1
(en)
|
2014-07-24 |
2016-01-28 |
Calithera Biosciences, Inc. |
Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
|
|
JP2017522332A
(ja)
|
2014-07-25 |
2017-08-10 |
バイエル ファーマ アクチエンゲゼルシャフト |
アミノ置換イソオキサゾール類
|
|
EP3174974B1
(en)
|
2014-07-29 |
2020-05-20 |
Novartis AG |
Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
|
|
TWI700283B
(zh)
|
2014-08-04 |
2020-08-01 |
德商拜耳製藥公司 |
２-(嗎啉-４-基)-１,７-萘啶
|
|
EP4180041A1
(en)
|
2014-08-07 |
2023-05-17 |
Mayo Foundation for Medical Education and Research |
Compounds and methods for treating cancer
|
|
GB201414464D0
(en)
|
2014-08-14 |
2014-10-01 |
Technion Res & Dev Foundation |
Compositions and methods for therapeutics prescreening
|
|
TWI560185B
(en)
|
2014-08-18 |
2016-12-01 |
Ono Pharmaceutical Co |
Acid addition salt of trk inhibitor compound
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
ES2756301T3
(es)
|
2014-08-19 |
2020-04-27 |
Univ California |
Implantes de administración localizada de fármacos y métodos de uso de los mismos
|
|
CN106604747A
(zh)
|
2014-08-26 |
2017-04-26 |
基础应用医学研究基金会 |
用于治疗和预防伴随认知缺陷或缺损的神经障碍以及神经变性疾病的产品
|
|
ES2695700T3
(es)
|
2014-08-29 |
2019-01-10 |
Gilead Sciences Inc |
Agentes antirretrovirales
|
|
US20160067255A1
(en)
|
2014-09-04 |
2016-03-10 |
Gilead Sciences, Inc. |
Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
|
|
US20170281624A1
(en)
|
2014-09-13 |
2017-10-05 |
Novartis Ag |
Combination therapies of alk inhibitors
|
|
EP3194401B1
(en)
|
2014-09-16 |
2020-10-21 |
Gilead Sciences, Inc. |
Solid forms of a toll-like receptor modulator
|
|
EA032401B1
(ru)
|
2014-09-19 |
2019-05-31 |
Байер Фарма Акциенгезельшафт |
Бензилзамещенные индазолы в качестве ингибиторов bub1
|
|
JP2017530963A
(ja)
|
2014-09-19 |
2017-10-19 |
バイエル ファーマ アクチエンゲゼルシャフト |
ベンジル置換インダゾール類
|
|
CA2961578A1
(en)
|
2014-09-19 |
2016-03-24 |
Bayer Pharma Aktiengesellschaft |
Benzyl substituted indazoles as bub1 kinase inhibitors
|
|
WO2016042081A1
(en)
|
2014-09-19 |
2016-03-24 |
Bayer Pharma Aktiengesellschaft |
Benzyl substituted indazoles as bub1 kinase inhibitors
|
|
JP6777638B2
(ja)
|
2014-09-19 |
2020-10-28 |
マッカイ メディカル ファンデーション ザ プレスビュテロス チャーチ イン タイワン マッカイ メモリアル ホスピタル |
ベンゾ複素環化合物および薬剤
|
|
SG11201702316SA
(en)
|
2014-09-24 |
2017-04-27 |
Cemm Forschungszentrum Für Molekulare Medizin Gmbh |
Monolayer of pbmcs or bone-marrow cells and uses thereof
|
|
CN104725628B
(zh)
|
2014-10-01 |
2018-04-17 |
厦门赛诺邦格生物科技股份有限公司 |
一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质
|
|
CN104530415B
(zh)
|
2014-10-01 |
2017-09-01 |
厦门赛诺邦格生物科技股份有限公司 |
一种异官能化y型聚乙二醇衍生物、制备方法及其生物相关物质
|
|
CN104530413B
(zh)
|
2014-10-01 |
2017-08-25 |
厦门赛诺邦格生物科技股份有限公司 |
一种多官能化h型聚乙二醇衍生物修饰的生物相关物质
|
|
EP3662903A3
(en)
|
2014-10-03 |
2020-10-14 |
Novartis AG |
Combination therapies
|
|
BR112017006305B1
(pt)
|
2014-10-06 |
2024-02-20 |
Merck Patent Gmbh |
Compostos heteroarila, seus usos, e composição farmacêutica
|
|
US9446148B2
(en)
|
2014-10-06 |
2016-09-20 |
Mayo Foundation For Medical Education And Research |
Carrier-antibody compositions and methods of making and using the same
|
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
ES2952717T3
(es)
|
2014-10-14 |
2023-11-03 |
Novartis Ag |
Moléculas de anticuerpos contra PD-L1 y usos de las mismas
|
|
KR20230004907A
(ko)
|
2014-10-14 |
2023-01-06 |
립타이드 바이오사이언스, 인코포레이티드 |
항-염증 특성을 갖는 펩타이드
|
|
WO2016061495A1
(en)
|
2014-10-16 |
2016-04-21 |
Predictive Therapeutics Ltd. |
Atavarsitic systems and methods for biomarker discovery
|
|
US10889812B2
(en)
|
2014-10-24 |
2021-01-12 |
University Of Maryland, Baltimore |
Short non-coding protein regulatory RNAs (sprRNAs) and methods of use
|
|
US20180289689A1
(en)
|
2014-10-27 |
2018-10-11 |
Ruprecht-Karls-Universität Heidelberg |
Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
|
|
AU2015341301B2
(en)
|
2014-10-30 |
2019-05-16 |
Kangpu Biopharmaceuticals, Ltd. |
Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
|
|
DK3212233T3
(da)
|
2014-10-31 |
2020-07-27 |
Oncomed Pharm Inc |
Kombinationsterapi til behandling af sygdom
|
|
BR112017008945A2
(pt)
|
2014-10-31 |
2018-01-16 |
Abbvie Biotherapeutics Inc |
Anticorpos anti-cs1 e conjugados fármaco- anticorpo
|
|
EP3215182B1
(en)
|
2014-11-05 |
2023-01-04 |
The Regents of The University of California |
Combination immunotherapy
|
|
WO2016071477A1
(en)
|
2014-11-07 |
2016-05-12 |
Rheinische Friedrich-Wilhelms-Universität Bonn Institut Für Rekonstruktive Neurobiologie |
Methods for assessing the treatment response of cancer patients and for treating cancer patients by analysing cpg methylation
|
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
PE20170912A1
(es)
|
2014-11-14 |
2017-07-12 |
Novartis Ag |
Conjugados de anticuerpo-farmaco
|
|
CN106999583A
(zh)
*
|
2014-11-17 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
|
|
EP3229810B1
(en)
|
2014-11-17 |
2020-07-22 |
Cellectar Biosciences, Inc. |
Phospholipid ether analogs as cancer-targeting drug vehicles
|
|
US10526341B2
(en)
|
2014-11-19 |
2020-01-07 |
Memorial Sloan-Kettering Cancer Center |
Thienopyrimidines and uses thereof
|
|
HUE047586T2
(hu)
|
2014-11-20 |
2020-04-28 |
Merck Patent Gmbh |
Heteroaril vegyületek mint IRAK inhibitorok és alkalmazásaik
|
|
US10179125B2
(en)
|
2014-12-01 |
2019-01-15 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
|
WO2016087936A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Corp. |
Substituted pyridinones as bromodomain inhibitors
|
|
US20180148789A1
(en)
|
2014-12-01 |
2018-05-31 |
University Of Southern California |
Methods for treating and assessing tumor invasion and metastasis
|
|
WO2016087490A1
(en)
|
2014-12-03 |
2016-06-09 |
Bayer Pharma Aktiengesellschaft |
Combination of pi3k-inhibitors
|
|
WO2016087488A1
(en)
|
2014-12-03 |
2016-06-09 |
Bayer Pharma Aktiengesellschaft |
Administration regime for aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives
|
|
CN107406508B
(zh)
|
2014-12-04 |
2022-04-05 |
地中海治疗诊断有限公司 |
人源化的抗trop-2单克隆抗体及其应用
|
|
CA2968352A1
(en)
|
2014-12-08 |
2016-06-16 |
Dana-Farber Cancer Institute, Inc. |
Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
|
|
SG10202012274RA
(en)
|
2014-12-09 |
2021-01-28 |
Bayer Ag |
1,3-thiazol-2-yl substituted benzamides
|
|
WO2016094309A1
(en)
|
2014-12-10 |
2016-06-16 |
Myosotis |
Inhibition of tnf signaling in cancer immunotherapy
|
|
DK3230736T3
(da)
|
2014-12-12 |
2020-06-08 |
Celcuity Inc |
Fremgangsmåder til måling af ErbB-signaleringsvejsaktivitet til at diagnosticere og behandle cancerpatienter
|
|
EP3233127A1
(de)
|
2014-12-15 |
2017-10-25 |
Bayer Pharma Aktiengesellschaft |
Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit aglycosylierten anti-tweakrantikörpern
|
|
US20190125745A1
(en)
|
2014-12-17 |
2019-05-02 |
Rgenix, Inc. |
Treatment and diagnosis of cancer
|
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
BR112017007662B1
(pt)
|
2014-12-18 |
2021-11-03 |
F. Hoffmann-La Roche Ag |
Composto, composição farmacêutica e uso de um composto
|
|
JP2017538727A
(ja)
|
2014-12-18 |
2017-12-28 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
癌の治療に有用な２，３−ジフェニルクロメンの誘導体
|
|
TN2017000256A1
(en)
|
2014-12-18 |
2018-10-19 |
Bayer Pharma AG |
Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
|
|
JP6807841B2
(ja)
|
2014-12-18 |
2021-01-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
エストロゲン受容体モジュレーター及びその使用
|
|
EP3540075B1
(en)
|
2014-12-19 |
2021-07-28 |
Epigenomics AG |
Methods for detecting cpg methylation and for diagnosing cancer
|
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
|
WO2016102493A1
(en)
|
2014-12-22 |
2016-06-30 |
Bayer Pharma Aktiengesellschaft |
Imidazopyridine ezh2 inhibitors
|
|
CA2971763A1
(en)
|
2014-12-23 |
2016-06-30 |
Bergenbio Asa |
Inhibitors of akt kinase
|
|
TWI695003B
(zh)
|
2014-12-23 |
2020-06-01 |
美商基利科學股份有限公司 |
多環胺甲醯基吡啶酮化合物及其醫藥用途
|
|
DE102014226903A1
(de)
|
2014-12-23 |
2016-06-23 |
Olympus Winter & Ibe Gmbh |
HF-Hilfsstoff, medizinisches System und Verfahren zum selektiven Behandeln von Krebsgewebe
|
|
WO2016102427A1
(en)
|
2014-12-23 |
2016-06-30 |
Bayer Pharma Aktiengesellschaft |
6-hydroxybenzofuranyl- and 6-alkoxybenzofuranyl-substituted imidazopyridazines
|
|
EA032430B1
(ru)
|
2014-12-24 |
2019-05-31 |
Джилид Сайэнс, Инк. |
Конденсированные пиримидины для лечения вич
|
|
TWI770552B
(zh)
|
2014-12-24 |
2022-07-11 |
美商基利科學股份有限公司 |
喹唑啉化合物
|
|
WO2016105534A1
(en)
|
2014-12-24 |
2016-06-30 |
Gilead Sciences, Inc. |
Isoquinoline compounds for the treatment of hiv
|
|
WO2016111947A2
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
|
CA2972846A1
(en)
|
2015-01-08 |
2016-07-14 |
Hackensack University Medical Center |
Ex vivo methods for minimizing risks and maximizing benefits of allogeneic blood and marrow transplantation
|
|
WO2016111834A1
(en)
|
2015-01-09 |
2016-07-14 |
Reiley Pharmaceuticals, Inc. |
Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
|
|
WO2016117666A1
(ja)
|
2015-01-23 |
2016-07-28 |
国立大学法人鹿児島大学 |
Ｈｉｖ－１感染細胞殺傷剤及びその用途
|
|
HK1245677A1
(zh)
|
2015-01-23 |
2018-08-31 |
Aclaris Therapeutics, Inc. |
用於治疗炎症和癌症的杂环itk抑制剂
|
|
BR112017016193B1
(pt)
|
2015-01-28 |
2023-02-23 |
Bayer Pharma Aktiengesellschaft |
Derivados de 4h-pirrolo[3,2-c]piridin-4-ona
|
|
SI3805222T1
(sl)
|
2015-01-30 |
2025-04-30 |
Oncoceutics, Inc. |
Derivati 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-heksahidroimidazo[1,2-a] pirido[3,4-e]pirimidin-5(1H)-ona, njihove soli in njihova uporaba v terapiji
|
|
TW201639573A
(zh)
|
2015-02-03 |
2016-11-16 |
吉李德科學股份有限公司 |
有關治療癌症之合併治療
|
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
NZ732538A
(en)
|
2015-02-05 |
2022-04-29 |
Merck Patent Gmbh |
Macrocyclic compounds as irak1/4 inhibitors and uses thereof
|
|
ES2841452T3
(es)
|
2015-02-06 |
2021-07-08 |
Merck Patent Gmbh |
Macrociclos de piridazinona como inhibidores de IRAK y sus usos
|
|
CA2975729A1
(en)
|
2015-02-12 |
2016-08-18 |
Beyondspring Pharmaceuticals, Inc. |
Use of plinabulin in combination with immune checkpoint inhibitors
|
|
WO2016133910A1
(en)
|
2015-02-17 |
2016-08-25 |
Cantex Pharmaceuticals, Inc. |
Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
|
|
WO2016133194A1
(ja)
|
2015-02-20 |
2016-08-25 |
第一三共株式会社 |
がんの併用治療法
|
|
SG11201705821XA
(en)
|
2015-03-02 |
2017-08-30 |
Rigel Pharmaceuticals Inc |
TGF-ß INHIBITORS
|
|
AU2016216673B2
(en)
|
2015-03-04 |
2017-02-02 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
BR112017019188A2
(pt)
|
2015-03-09 |
2018-04-24 |
Bayer Pharma Aktiengesellschaft |
Combinações contendo 2,3-di-hidroimidazo[1,2-c] quinazolina substituídas
|
|
SG11201707239WA
(en)
|
2015-03-09 |
2017-10-30 |
Bayer Pharma AG |
Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
|
|
US20180271891A1
(en)
|
2015-03-11 |
2018-09-27 |
The Broad Institute Inc. |
Selective treatment of prmt5 dependent cancer
|
|
ES2900632T3
(es)
|
2015-03-13 |
2022-03-17 |
Fond Telethon |
Células T CD4+ productoras de IL-10 para uso en el tratamiento de un cáncer
|
|
US10946050B2
(en)
|
2015-03-16 |
2021-03-16 |
Imagilin Technology Llc |
Compositions comprising probiotics and methods of use thereof
|
|
WO2016149366A1
(en)
|
2015-03-16 |
2016-09-22 |
The Johns Hopkins University |
Methods and compositions for treating cancer
|
|
US10195237B2
(en)
|
2015-03-16 |
2019-02-05 |
Imagilin Technology Llc |
Compositions and methods for treating inflammatory related diseases or conditions using Pediococcus acidilactici probiotics
|
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US20180044418A1
(en)
|
2015-03-20 |
2018-02-15 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and vorinostat for treating cancer
|
|
WO2016153948A1
(en)
|
2015-03-20 |
2016-09-29 |
Deuterx, Llc |
Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders
|
|
ES2986548T3
(es)
|
2015-03-20 |
2024-11-11 |
Syndax Pharmaceuticals Inc |
Combinación de inhibidor de HDAC y anticuerpo anti-PD-1 para el tratamiento del cáncer, en donde la combinación no comprende 5-azacitidina
|
|
US10745667B2
(en)
|
2015-03-23 |
2020-08-18 |
Yao Tang |
Methods of primary tissue culture and drug screening using autologous serum and fluids
|
|
AU2016238290B9
(en)
|
2015-03-25 |
2019-06-13 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
US10302629B2
(en)
|
2015-03-30 |
2019-05-28 |
University Of Maryland, Baltimore |
Compositions and methods for treating cancer by rational targeting of protein translation
|
|
US9630978B2
(en)
|
2015-04-02 |
2017-04-25 |
Gilead Sciences, Inc. |
Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
|
|
KR102528825B1
(ko)
|
2015-04-13 |
2023-05-08 |
화이자 인코포레이티드 |
B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
|
|
WO2016166600A1
(en)
|
2015-04-15 |
2016-10-20 |
Trojantec Technologies Ltd |
Delivery of microrna using mesenchymal stem cell microparticles
|
|
WO2016168721A1
(en)
|
2015-04-17 |
2016-10-20 |
The Trustees Of The University Of Pennsylvania |
Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy
|
|
CA2984195C
(en)
|
2015-04-29 |
2023-10-24 |
Radius Pharmaceuticals, Inc. |
Use of rad1901 in the treatment of cancer
|
|
CA2984259C
(en)
|
2015-04-30 |
2024-02-13 |
Bayer Pharma Aktiengesellschaft |
Combinations of inhibitors of irak4 with inhibitors of btk
|
|
WO2016177833A1
(en)
|
2015-05-04 |
2016-11-10 |
Bionor Immuno As |
Dosage regimen for hiv vaccine
|
|
CA2984848A1
(en)
|
2015-05-05 |
2016-11-10 |
Bayer Pharma Aktiengesellschaft |
Amido-substituted cyclohexane derivatives
|
|
WO2016183071A1
(en)
*
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Hetero-tricyclic compounds and their use for the treatment of cancer
|
|
WO2016187122A1
(en)
|
2015-05-15 |
2016-11-24 |
University Of Iowa Research Foundation |
Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
|
|
WO2016184962A1
(en)
|
2015-05-19 |
2016-11-24 |
Innavirvax |
Treatment of hiv-infected individuals
|
|
WO2016184973A1
(en)
|
2015-05-19 |
2016-11-24 |
Innavirvax |
Treatment of hiv-infected individuals
|
|
US20160339030A1
(en)
|
2015-05-19 |
2016-11-24 |
University Of Maryland, Baltimore |
Treatment agents for inhibiting hiv and cancer in hiv infected patients
|
|
WO2016184963A1
(en)
|
2015-05-19 |
2016-11-24 |
Innavirvax |
Treatment of hiv-infected individuals
|
|
HK1252267A1
(zh)
|
2015-05-20 |
2019-05-24 |
The Broad Institute Inc. |
共有的新抗原
|
|
JP6841771B2
(ja)
|
2015-05-21 |
2021-03-10 |
ケモセントリックス，インコーポレイティド |
Ｃｃｒ２モジュレータ
|
|
US10493030B2
(en)
|
2015-05-22 |
2019-12-03 |
Aphios Corporation |
Combination HIV therapeutic
|
|
JP6768711B2
(ja)
|
2015-05-26 |
2020-10-14 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
複素環式エストロゲン受容体モジュレーター及びその使用
|
|
CN104892648A
(zh)
|
2015-05-27 |
2015-09-09 |
天津工业大学 |
一种负载抗肿瘤药物的靶向金属有机骨架的制备及用途
|
|
EP3304080A1
(en)
|
2015-05-28 |
2018-04-11 |
Bayer Pharma Aktiengesellschaft |
Method for stratification of melanoma patients by determination of oxygen consumption, ppargc1a, ppargc1b and mitf levels
|
|
WO2016196471A1
(en)
|
2015-06-02 |
2016-12-08 |
Cooper Human Systems Llc |
Methods and compositions for treatment of hiv infection
|
|
EP3302465A1
(en)
|
2015-06-05 |
2018-04-11 |
Vertex Pharmaceuticals Incorporated |
Triazoles for the treatment of demyelinating diseases
|
|
JP6721252B2
(ja)
|
2015-06-05 |
2020-07-08 |
ミラゲン セラピューティクス， インコーポレイテッド |
皮膚Ｔ細胞リンパ腫（ＣＴＣＬ）を処置するためのｍｉＲ−１５５阻害剤
|
|
WO2016198322A1
(en)
|
2015-06-08 |
2016-12-15 |
Bayer Pharma Aktiengesellschaft |
N-menthylbenzimidazoles as midh1 inhibitors
|
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
CA2989269C
(en)
|
2015-06-15 |
2020-09-22 |
Robert Yongxin Zhao |
Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule
|
|
WO2016205551A2
(en)
|
2015-06-16 |
2016-12-22 |
The Regents Of The University Of California |
Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
|
|
WO2016205566A1
(en)
|
2015-06-16 |
2016-12-22 |
The Regents Of The University Of California |
Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
|
|
US10975112B2
(en)
|
2015-06-16 |
2021-04-13 |
Hangzhou Dac Biotech Co., Ltd. |
Linkers for conjugation of cell-binding molecules
|
|
WO2016202758A1
(en)
|
2015-06-18 |
2016-12-22 |
Bayer Pharma Aktiengesellschaft |
Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
|
|
WO2016202756A1
(en)
|
2015-06-18 |
2016-12-22 |
Bayer Pharma Aktiengesellschaft |
Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
|
|
CN116712552A
(zh)
|
2015-06-19 |
2023-09-08 |
波士顿大学托管委员会 |
用于治疗疱疹病毒诱导的病况的方法和组合物
|
|
WO2015151079A2
(en)
|
2015-06-20 |
2015-10-08 |
Hangzhou Dac Biotech Co, Ltd |
Auristatin analogues and their conjugates with cell-binding molecules
|
|
CA2990076A1
(en)
|
2015-06-22 |
2016-12-29 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
|
|
US10744205B2
(en)
|
2015-06-23 |
2020-08-18 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies
|
|
PE20180452A1
(es)
|
2015-06-23 |
2018-03-05 |
Bayer Pharma AG |
Conjugados homogeneos especificos de sitio con inhibidores de ksp
|
|
WO2016207094A1
(de)
|
2015-06-23 |
2016-12-29 |
Bayer Pharma Aktiengesellschaft |
Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern
|
|
US20190070154A1
(en)
|
2015-06-24 |
2019-03-07 |
Duke University |
New methods of use for an anti-diarrhea agent
|
|
EP3313388A4
(en)
|
2015-06-24 |
2019-05-15 |
Duke University |
CHEMICAL MODULATORS OF SIGNALING PATHS AND THERAPEUTIC USE
|
|
CA2990687A1
(en)
|
2015-06-29 |
2017-01-05 |
Syndax Pharmaceuticals, Inc. |
Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
|
|
CA2990705A1
(en)
|
2015-06-29 |
2017-01-05 |
Abraxis Bioscience, Llc |
Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy
|
|
WO2017003995A1
(en)
|
2015-06-29 |
2017-01-05 |
Merck Patent Gmbh |
TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF
|
|
HK1247093A1
(zh)
|
2015-06-29 |
2018-09-21 |
阿布拉科斯生物科学有限公司 |
使用纳米颗粒mtor抑制剂联合疗法治疗实体瘤的方法
|
|
UY36758A
(es)
|
2015-06-30 |
2016-12-30 |
Glaxosmithkline Ip No 2 Ltd |
Inhibidores del potenciador del homólogo zeste 2
|
|
US10925852B2
(en)
|
2015-06-30 |
2021-02-23 |
The Trustees Of Columbia University In The City Of New York |
Talc-bound compositions and uses thereof
|
|
CA2991384C
(en)
|
2015-07-04 |
2022-11-08 |
Suzhou M-Conj Biotech Co., Ltd |
Bridge linkers for conjugation of a cell-binding molecule
|
|
EP3319945B1
(en)
|
2015-07-07 |
2021-04-28 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors
|
|
US20180371550A1
(en)
|
2015-07-08 |
2018-12-27 |
Children's Hospital Medical Center |
Loss of transcriptional fidelity leads to immunotherapy resistance in cancers
|
|
WO2017005711A1
(de)
|
2015-07-09 |
2017-01-12 |
Bayer Pharma Aktiengesellschaft |
Phosphor- und schwefel-substituierte benzodiazepin-derivate
|
|
AU2016290950A1
(en)
|
2015-07-09 |
2018-01-18 |
Merck Patent Gmbh |
Pyrimidine derivatives as BTK inhibitors and uses thereof
|
|
US10292961B2
(en)
|
2015-07-15 |
2019-05-21 |
Hangzhou Dac Biotech Co., Ltd. |
Disulfur bridge linkers for conjugation of a cell-binding molecule
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
EP3322694B1
(en)
|
2015-07-16 |
2020-02-19 |
Bayer Pharma Aktiengesellschaft |
5-hydroxyalkylbenzimidazoles as midh1 inhibitors
|
|
EP3121166A1
(en)
|
2015-07-21 |
2017-01-25 |
Bayer Pharma Aktiengesellschaft |
Fused imidazoles as midh1 inhibitors
|
|
GB201512869D0
(en)
|
2015-07-21 |
2015-09-02 |
Almac Diagnostics Ltd |
Gene signature for minute therapies
|
|
WO2017019767A1
(en)
|
2015-07-27 |
2017-02-02 |
Myosotis, Llc |
Inhibition of CXCL12 in Cancer Immunotherapy
|
|
KR20180072665A
(ko)
|
2015-07-28 |
2018-06-29 |
베타 캐트 파마슈티칼스, 인코포레이티드 |
안트라센-9,10-디온 디옥심 화합물 전구약물 및 이의 용도
|
|
ES2939084T3
(es)
|
2015-07-29 |
2023-04-18 |
Onk Therapeutics Ltd |
Células asesinas naturales y líneas de células asesinas naturales modificadas que tienen citotoxicidad aumentada
|
|
EP3124609A1
(en)
|
2015-07-29 |
2017-02-01 |
IFOM Fondazione Istituto Firc di Oncologia Molecolare |
Therapeutics oligonucleotides
|
|
JP6878405B2
(ja)
|
2015-07-29 |
2021-05-26 |
ノバルティス アーゲー |
Ｐｄ−１に対する抗体分子を含む組み合わせ治療
|
|
PT3317301T
(pt)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Terapias de associação compreendendo moléculas de anticorpo contra lag-3
|
|
PL3330267T3
(pl)
|
2015-07-29 |
2022-04-04 |
Shionogi&Co., Ltd. |
Sól pochodnej chinazoliny lub jej kryształ oraz sposób wytwarzania soli pochodnej chinazoliny lub jej kryształu
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
CA2991868C
(en)
|
2015-07-31 |
2025-05-27 |
Immunewalk Therapeutics, Inc. |
PROTEIN 2 CONTAINING THE MOTILE SPERM DOMAIN AND CANCER
|
|
WO2017024009A1
(en)
|
2015-08-03 |
2017-02-09 |
Quadriga Biosciences, Inc. |
Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof
|
|
WO2017021348A1
(en)
|
2015-08-05 |
2017-02-09 |
Bayer Pharma Aktiengesellschaft |
1h-pyrrol-3-amines
|
|
WO2017023994A1
(en)
|
2015-08-06 |
2017-02-09 |
Yale University |
Small molecule based antibody-recruiting compounds for cancer treatment
|
|
CA2993624A1
(en)
|
2015-08-07 |
2017-02-16 |
Thomas Helledays Stiftelse For Medicinsk Forskning |
Method for diagnosisng cancer or cancer-associated thrombosis by measuring levels of h3cit in plasma
|
|
CN108136023B
(zh)
|
2015-08-12 |
2021-07-27 |
北卡罗莱纳州立大学 |
血小板膜包覆的药物递送系统
|
|
WO2017025493A1
(en)
|
2015-08-12 |
2017-02-16 |
Bayer Pharma Aktiengesellschaft |
Quinoline ezh2 inhibitors
|
|
US10633399B2
(en)
|
2015-08-17 |
2020-04-28 |
Channel Therapeutics, Inc. |
Functionalized aminobenzoboroxoles
|
|
EP3133165A1
(en)
|
2015-08-17 |
2017-02-22 |
F. Hoffmann-La Roche AG |
Methods for personalizing patient cancer therapy with anti angiogenic compounds
|
|
GB201514756D0
(en)
|
2015-08-19 |
2015-09-30 |
Karus Therapeutics Ltd |
Compound and method of use
|
|
WO2017034234A1
(ko)
|
2015-08-21 |
2017-03-02 |
서울대학교 산학협력단 |
Hdac 억제제 내성을 갖는 암 치료용 복합제제
|
|
US20170056352A1
(en)
|
2015-08-25 |
2017-03-02 |
Rgenix, Inc. |
PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
|
|
JP2018525412A
(ja)
|
2015-08-26 |
2018-09-06 |
ギリアード サイエンシーズ， インコーポレイテッド |
重水素化トール様受容体調節因子
|
|
WO2017035453A1
(en)
|
2015-08-26 |
2017-03-02 |
The Johns Hopkins University |
Compositions and methods for treating solid tumors
|
|
JP6917375B2
(ja)
|
2015-09-01 |
2021-08-11 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
血液がんの治療または予防に有用な化合物および方法
|
|
MX2018002640A
(es)
|
2015-09-02 |
2018-06-20 |
Syndax Pharmaceuticals Inc |
Seleccion de pacientes para la terapia de combinacion.
|
|
US10588985B2
(en)
|
2015-09-02 |
2020-03-17 |
Wayne State University |
Compositions and methods relating to RAD6 inhibition
|
|
EP3344275B8
(en)
|
2015-09-03 |
2023-04-12 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
|
DE102015012049A1
(de)
|
2015-09-15 |
2017-03-16 |
Merck Patent Gmbh |
Verbindungen als ASIC-Inhibitoren und deren Verwendungen
|
|
DE102015012050A1
(de)
|
2015-09-15 |
2017-03-16 |
Merck Patent Gmbh |
Verbindungen als ASIC-Inhibitoren und deren Verwendungen
|
|
EP3350316B1
(en)
|
2015-09-15 |
2024-05-08 |
Stichting Radboud universitair medisch centrum |
IMPROVED METHOD FOR EX VIVO EXPANSION CD34+HSPCs INTO NK CELLS USING AN ARYL HYDROCARBON RECEPTOR ANTAGONIST
|
|
MX383707B
(es)
|
2015-09-18 |
2025-03-14 |
Merck Patent Gmbh |
Compuestos de heteroarilo como inhibidores de cinasas asociadas a receptor de interleucina-1 (irak) y usos de los mismos.
|
|
EP3350170B1
(en)
|
2015-09-18 |
2022-01-26 |
Merck Patent GmbH |
Heteroaryl compounds as irak inhibitors and uses thereof
|
|
EP3349893A4
(en)
|
2015-09-20 |
2019-09-11 |
Air Cross Inc. |
OZONOLYSIS FOR THE ACTIVATION OF COMPOUNDS AND REMOVAL OF OZONE
|
|
ES2913048T3
(es)
|
2015-09-21 |
2022-05-31 |
Opna Immuno Oncology Sa |
Compuestos heterocíclicos y usos de estos
|
|
CN108601838A
(zh)
|
2015-09-21 |
2018-09-28 |
意大利癌症研究基金会分子肿瘤学研究所(Ifom) |
对抗血液癌症的新治疗策略
|
|
WO2017053823A1
(en)
|
2015-09-25 |
2017-03-30 |
Pharmacyclics Llc |
Treatment using hdac inhibitors and immunotherapy
|
|
KR102053556B1
(ko)
|
2015-09-29 |
2020-01-08 |
강푸 바이오파마슈티칼즈 리미티드 |
약물 조성물 및 이의 응용
|
|
NZ741785A
(en)
|
2015-09-30 |
2019-07-26 |
Gilead Sciences Inc |
3-cyano-1h-1,2,4-triazol-1-yl compounds and uses thereof for the treatment of hiv
|
|
WO2017055313A1
(en)
|
2015-10-01 |
2017-04-06 |
Bayer Pharma Aktiengesellschaft |
Amido-substituted azole compounds
|
|
US20190054090A1
(en)
|
2015-10-01 |
2019-02-21 |
Gilead Sciences, Inc. |
Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
|
|
WO2017055316A1
(en)
|
2015-10-01 |
2017-04-06 |
Bayer Pharma Aktiengesellschaft |
Amido-substituted azole compounds
|
|
EP3355888B8
(en)
|
2015-10-02 |
2022-04-13 |
Pierre Fabre Medicament |
Hemi-synthetic trilobine analogs for use as a drug
|
|
EP3355871A1
(en)
|
2015-10-02 |
2018-08-08 |
Gilead Sciences, Inc. |
Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases
|
|
HRP20210960T1
(hr)
|
2015-10-09 |
2021-09-03 |
Boehringer Ingelheim International Gmbh |
Spojevi i derivati spiro[3h-indol-3,2’-pirolidin]-2(1h)-ona kao inhibitori mdm2-p53
|
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
|
WO2017063966A1
(en)
|
2015-10-13 |
2017-04-20 |
Bayer Pharma Aktiengesellschaft |
Substituted 2-(1h-pyrazol-1-yl)-benzothiazole compounds
|
|
CN105288648B
(zh)
|
2015-10-14 |
2018-11-06 |
东南大学 |
一种亲水性药物的磷脂化合物、其药物组合物及应用
|
|
CA3002066A1
(en)
|
2015-10-15 |
2017-04-20 |
Celularity Inc. |
Natural killer cells and ilc3 cells and uses thereof
|
|
WO2017063959A1
(de)
|
2015-10-15 |
2017-04-20 |
Bayer Pharma Aktiengesellschaft |
N-sulfoximinophenyl-substituierte benzodiazepin-derivate als bet-proteininhibitoren
|
|
EP3365468A4
(en)
|
2015-10-19 |
2019-07-31 |
Dana-Farber Cancer Institute, Inc. |
POLYMERASE Q AS A GOAL FOR HR DEFICIENT CANCER
|
|
US20170115275A1
(en)
|
2015-10-23 |
2017-04-27 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Engineered substrates for high-throughput generation of 3d models of tumor dormancy, relapse and micrometastases for phenotype specific drug discovery and development
|
|
HK1253320A1
(zh)
|
2015-10-23 |
2019-06-14 |
Daiichi Sankyo Company, Limited |
用於治疗aml的药物组合物和治疗有此需要的对象中的aml的方法
|
|
TWI806822B
(zh)
|
2015-10-23 |
2023-07-01 |
日商第一三共股份有限公司 |
製備治療癌症之醫藥組成物之用途
|
|
US11492670B2
(en)
|
2015-10-27 |
2022-11-08 |
The Broad Institute Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
EP4046655A1
(en)
|
2015-11-03 |
2022-08-24 |
Janssen Biotech, Inc. |
Antibodies specifically binding pd-1 and their uses
|
|
US20190038713A1
(en)
|
2015-11-07 |
2019-02-07 |
Multivir Inc. |
Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
|
CN105457038A
(zh)
|
2015-11-09 |
2016-04-06 |
东南大学 |
一种速释型药物磷脂化合物及其药物组合物
|
|
RU2761980C2
(ru)
|
2015-11-10 |
2021-12-14 |
Йейл Юниверсити |
Композиции и способы лечения аутоиммунных заболеваний и рака
|
|
ES2922981T3
(es)
|
2015-11-12 |
2022-09-22 |
Hookipa Biotech Gmbh |
Partículas de arenavirus como vacunas contra el cáncer
|
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
TWI724056B
(zh)
|
2015-11-19 |
2021-04-11 |
美商卡默森屈有限公司 |
Ｃｘｃｒ２抑制劑
|
|
TWI734715B
(zh)
|
2015-11-19 |
2021-08-01 |
美商卡默森屈有限公司 |
趨化因子受體調節劑
|
|
CN108601789A
(zh)
|
2015-11-20 |
2018-09-28 |
生华生物科技股份有限公司 |
用于治疗癌症的四环喹诺酮类似物组合疗法
|
|
WO2017091777A1
(en)
|
2015-11-24 |
2017-06-01 |
Vijay Krishnan |
Novel healthcare delivery, treatment, and payment model for specialty drugs
|
|
CA3007031A1
(en)
|
2015-12-01 |
2017-06-08 |
Genmab B.V. |
Anti-death receptor antibodies and methods of use thereof
|
|
US10722529B2
(en)
|
2015-12-03 |
2020-07-28 |
Temple University—Of the Commonwealth System of Higher Education |
Modulation of NAD+ metabolic pathways for treatment of disease
|
|
EP3383865B1
(en)
|
2015-12-03 |
2020-01-29 |
Bayer Pharma Aktiengesellschaft |
Furane derivatives as inhibitors of atad2
|
|
KR20180088690A
(ko)
|
2015-12-03 |
2018-08-06 |
알프레드 헬스 |
골수종의 치료 또는 진행의 모니터링
|
|
TWI734719B
(zh)
|
2015-12-04 |
2021-08-01 |
德商百靈佳殷格翰國際股份有限公司 |
在腫瘤細胞中拮抗ｗｎｔ信號傳遞之雙抗體結合部位（ｂｉｐａｒａｔｏｐｉｃ）多肽
|
|
CN106821965A
(zh)
|
2015-12-04 |
2017-06-13 |
中国科学院大连化学物理研究所 |
一种维甲酸多药共递送纳米粒溶液及其制备和应用
|
|
SI3386997T1
(sl)
|
2015-12-09 |
2021-11-30 |
Medizinische Universitaet Wien |
Spojine platine s funkcionalnimi monomaleimidi za zdravljenje raka
|
|
US10969392B2
(en)
|
2015-12-10 |
2021-04-06 |
Vanderbilt University |
Methods and systems for predicting response to immunotherapies for treatment of cancer
|
|
TWI814056B
(zh)
|
2015-12-15 |
2023-09-01 |
美商基利科學股份有限公司 |
人類免疫不全病毒中和抗體
|
|
WO2017106129A1
(en)
|
2015-12-16 |
2017-06-22 |
Merck Sharp & Dohme Corp. |
Anti-lag3 antibodies and antigen-binding fragments
|
|
CN108602820A
(zh)
|
2015-12-16 |
2018-09-28 |
拜耳制药股份公司 |
杂-1,5,6,7-四氢-4h-吲哚-4-酮类化合物
|
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Ｐｄ−１に対する抗体分子およびその使用
|
|
US10316049B2
(en)
|
2015-12-17 |
2019-06-11 |
Gilead Sciences, Inc. |
Tank-binding kinase inhibitor compounds
|
|
PT3889145T
(pt)
|
2015-12-17 |
2024-04-02 |
Merck Patent Gmbh |
8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários
|
|
US10894784B2
(en)
|
2015-12-18 |
2021-01-19 |
Bayer Pharma Aktiengesellschaft |
Heteroarylbenzimidazole compounds
|
|
CA3008102A1
(en)
|
2015-12-18 |
2017-06-22 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
EP3393458A4
(en)
|
2015-12-22 |
2019-08-14 |
GlaxoSmithKline LLC |
METHOD OF USE OF A CLASS IIA HDAC HEMMER
|
|
JP2019502753A
(ja)
|
2015-12-23 |
2019-01-31 |
ムーンショット ファーマ エルエルシー |
ナンセンス変異依存ｍＲＮＡ分解機構の抑制による免疫応答の誘導法
|
|
BR112018013094A2
(pt)
|
2015-12-28 |
2018-12-11 |
Merck Patent Gmbh |
combinação de inibidor de hdac e anticorpo de anti-pd-l1 para o tratamento de câncer ovariano
|
|
US10189797B2
(en)
|
2015-12-30 |
2019-01-29 |
Duke University |
Chemical modulators of immune checkpoints and therapeutic use
|
|
US11834675B2
(en)
|
2015-12-30 |
2023-12-05 |
Celgene Corporation |
T lymphocyte production methods and t lymphocytes produced thereby
|
|
US20190183870A1
(en)
|
2016-01-05 |
2019-06-20 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Combination of histone deacetylase inhibitor and immunotherapy
|
|
EP3400292B1
(en)
|
2016-01-08 |
2020-08-26 |
Replimune Limited |
Use of an oncolytic virus for the treatment of cancer
|
|
EP3402477A4
(en)
|
2016-01-11 |
2019-08-21 |
The Rockefeller University |
METHOD FOR THE TREATMENT OF DISEASES RELATED TO MYELOID-DERIVED SUPPRESSOR CELLS
|
|
US10729680B2
(en)
|
2016-01-14 |
2020-08-04 |
Bayer Pharma Aktiengesellschaft |
5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
|
|
MX2018008771A
(es)
|
2016-01-19 |
2018-11-09 |
Janssen Pharmaceutica Nv |
Formulaciones/composiciones que comprenden un inhibidor de btk.
|
|
EP3405790B1
(en)
|
2016-01-19 |
2023-06-28 |
Celgene Corporation |
Transgenic mouse expressing human cereblon
|
|
WO2017132541A1
(en)
|
2016-01-27 |
2017-08-03 |
University Of Maryland, Baltimore |
A method for monitoring cancer and for regulation of semaphorin 4d to improve cancer immunotherapy regimens
|
|
CA3013047A1
(en)
|
2016-01-28 |
2017-08-03 |
Indiana University Research & Technology Corporation |
Use of histone deacetylase inhibitors for enhancing immunotherapies
|
|
ES2849559T3
(es)
|
2016-01-29 |
2021-08-19 |
Epigenomics Ag |
Métodos para detectar metilación CpG de ADN derivado de tumor en muestras de sangre
|
|
GB201601773D0
(en)
|
2016-02-01 |
2016-03-16 |
Renishaw Plc |
Method
|
|
CN109072307A
(zh)
|
2016-02-01 |
2018-12-21 |
拜耳制药股份公司 |
Copanlisib生物标志物
|
|
CN108884496A
(zh)
|
2016-02-01 |
2018-11-23 |
拜耳制药股份公司 |
Copanlisib生物标志物
|
|
US11078277B2
(en)
|
2016-02-02 |
2021-08-03 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer
|
|
WO2017136342A1
(en)
|
2016-02-02 |
2017-08-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
|
|
HK1259487A1
(zh)
|
2016-02-04 |
2019-11-29 |
Hangzhou Dac Biotech Co. Ltd. |
特定的共轭连接子，特定的免疫共轭物，制造和使用这些共轭物的方法
|
|
EP3411037B1
(en)
|
2016-02-05 |
2021-10-20 |
Bayer Pharma Aktiengesellschaft |
Compounds, compositions and methods for cancer patient stratification and cancer treatment
|
|
SG11201806583XA
(en)
|
2016-02-08 |
2018-09-27 |
Beyondspring Pharmaceuticals Inc |
Compositions containing tucaresol or its analogs
|
|
EP3413914A4
(en)
|
2016-02-10 |
2019-10-16 |
Immunomedics, Inc. |
COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) TO OVERCOME THE RESISTANCE TO SN-38 IN TROP-2-EXPRESSIVE CANCER
|
|
WO2017143035A2
(en)
|
2016-02-17 |
2017-08-24 |
The Penn State Research Foundation |
Method and therapeutic use of pign and other genes or genes products that pign interacts with for prognosis and treatment of hematological neoplasias
|
|
US11311540B2
(en)
|
2016-02-17 |
2022-04-26 |
Acetylon Pharmaceuticals, Inc. |
Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs
|
|
CA3015241A1
(en)
|
2016-02-22 |
2017-08-31 |
Onxeo |
Combination therapies comprising immuno-oncology agents and belinostat
|
|
EP3420075A4
(en)
|
2016-02-23 |
2019-10-16 |
Chaya Brodie |
GENERATION OF CANCER STEM CELLS AND USE THEREOF
|
|
US20170247690A1
(en)
|
2016-02-25 |
2017-08-31 |
Agenovir Corporation |
Oncoviral treatment with nuclease and chemotherapeutic
|
|
WO2017148995A1
(en)
|
2016-03-04 |
2017-09-08 |
Bayer Pharma Aktiengesellschaft |
1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
|
|
AU2017228371A1
(en)
|
2016-03-04 |
2018-09-13 |
Gilead Sciences, Inc. |
Compositions and combinations of autotaxin inhibitors
|
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
JP7157981B2
(ja)
|
2016-03-07 |
2022-10-21 |
チャールストンファーマ， エルエルシー |
抗ヌクレオリン抗体
|
|
WO2017156147A1
(en)
|
2016-03-08 |
2017-09-14 |
The Board Of Regents For Oklahoma State University Office Of Intellectual Property Management Technology Development Center |
Immune boosting dietary compounds for disease control and prevention
|
|
CN108884098B
(zh)
|
2016-03-08 |
2021-09-14 |
拜耳制药股份公司 |
2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类
|
|
EP3429613A4
(en)
|
2016-03-14 |
2020-01-15 |
Kiromic, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS
|
|
US20190077856A1
(en)
|
2016-03-15 |
2019-03-14 |
Memorial Sloan Kettering Cancer Center |
Method of treating diseases using kinase modulators
|
|
WO2017157418A1
(en)
|
2016-03-15 |
2017-09-21 |
Bayer Pharma Aktiengesellschaft |
Combination of mknk1-inhibitors
|
|
US20170268001A1
(en)
|
2016-03-16 |
2017-09-21 |
The University Of Chicago |
Rnas with tumor radio/chemo-sensitizing and immunomodulatory properties and methods of their preparation and application
|
|
EP3219329A1
(en)
|
2016-03-17 |
2017-09-20 |
Bayer Pharma Aktiengesellschaft |
Combinations of copanlisib
|
|
WO2017157992A1
(en)
|
2016-03-18 |
2017-09-21 |
Bayer Pharma Aktiengesellschaft |
Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
|
|
RU2018136593A
(ru)
|
2016-03-18 |
2020-04-20 |
Просепт Байороботикс Корпорейшн |
Минимально инвазивные способы и системы для гемостаза в кровоточащем закрытом объеме ткани
|
|
WO2017157991A1
(en)
|
2016-03-18 |
2017-09-21 |
Bayer Pharma Aktiengesellschaft |
1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
|
|
US20170273926A1
(en)
|
2016-03-24 |
2017-09-28 |
Orbus Therapeutics, Inc. |
Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
|
|
TWI808055B
(zh)
|
2016-05-11 |
2023-07-11 |
美商滬亞生物國際有限公司 |
Hdac 抑制劑與 pd-1 抑制劑之組合治療
|
|
TWI794171B
(zh)
|
2016-05-11 |
2023-03-01 |
美商滬亞生物國際有限公司 |
Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
|
|
CN105949114A
(zh)
|
2016-06-27 |
2016-09-21 |
山东川成医药股份有限公司 |
一种西达本胺的合成方法
|
|
WO2018016563A1
(en)
|
2016-07-20 |
2018-01-25 |
Eisai R&D Management Co., Ltd. |
Use of eribulin and histone deacetylase inhibitors in the treatment of cancer
|
|
CN106866571B
(zh)
|
2017-01-20 |
2018-06-29 |
中国药科大学 |
杂环脲类化合物及其药物组合物和应用
|
|
PL3581182T3
(pl)
|
2017-02-13 |
2022-01-17 |
Kangpu Biopharmaceuticals, Ltd. |
Kombinacja lecząca nowotwór złośliwy gruczołu krokowego, kompozycja farmaceutyczna i sposób leczenia
|
|
CN106916101B
(zh)
|
2017-02-15 |
2020-05-01 |
聚缘（上海）生物科技有限公司 |
Nampt/hdac双靶点抑制剂及其制备方法
|
|
CN107011238B
(zh)
|
2017-03-14 |
2020-05-01 |
北京化工大学 |
一类组蛋白去乙酰化酶抑制剂及其制备方法和用途
|
|
WO2018218137A1
(en)
|
2017-05-25 |
2018-11-29 |
Leidos, Inc. |
Pd-1 and ctla-4 dual inhibitor peptides
|
|
US20190046513A1
(en)
|
2017-08-10 |
2019-02-14 |
Huya Bioscience International, Llc |
Combination therapies of hdac inhibitors and tubulin inhibitors
|